Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI113295

Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells.

J H Kehrl, M Dukovich, G Whalen, P Katz, A S Fauci, and W C Greene

Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland 20892.

Find articles by Kehrl, J. in: JCI | PubMed | Google Scholar

Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland 20892.

Find articles by Dukovich, M. in: JCI | PubMed | Google Scholar

Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland 20892.

Find articles by Whalen, G. in: JCI | PubMed | Google Scholar

Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland 20892.

Find articles by Katz, P. in: JCI | PubMed | Google Scholar

Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland 20892.

Find articles by Fauci, A. in: JCI | PubMed | Google Scholar

Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland 20892.

Find articles by Greene, W. in: JCI | PubMed | Google Scholar

Published January 1, 1988 - More info

Published in Volume 81, Issue 1 on January 1, 1988
J Clin Invest. 1988;81(1):200–205. https://doi.org/10.1172/JCI113295.
© 1988 The American Society for Clinical Investigation
Published January 1, 1988 - Version history
View PDF
Abstract

A novel IL-2 receptor, distinct from the Tac protein, has been identified on the surface of purified human natural killer (NK) cells by chemical cross-linking of 125I-IL-2. This protein is approximately 70,000 D in size (p70) and appears to be identical to the recently recognized second subunit of the human high affinity IL-2 receptor complex. Scatchard analysis of 125I-IL-2 binding to purified NK cells revealed approximately 2,300 p70 binding sites per cell with an apparent dissociation constant of 200 pM, a value intermediate between the previously recognized high and low affinity forms of the human IL-2 receptor. The monoclonal anti-Tac antibody did not inhibit the cross-linking of 125I-IL-2 to the p70 binding sites present on NK cells. Functionally, the addition of high concentrations of recombinant IL-2 to the enriched NK cells promoted a rapid augmentation of cytolytic activity and a more delayed increase in cellular proliferation. Anti-Tac effectively blocked the IL-2-induced proliferative response in these cells, but failed to alter the enhancement of cytotoxicity. Analysis of NK cytoplasmic RNA isolated at various time points after IL-2 stimulation revealed the rapid induction of c-myb and Tac gene expression that was also not inhibited by the anti-Tac antibody. These findings suggest that IL-2 binding to the p70 receptor constitutively expressed on the surface of NK cells may mediate both the development of increased cytolytic activity and rapid changes in gene expression. The activation of the Tac gene may in turn permit the formation of the high affinity IL-2 receptor complex (comprised of at least the Tac and p70 proteins) that appears to transduce the requisite signals involved in NK cell proliferation.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 200
page 200
icon of scanned page 201
page 201
icon of scanned page 202
page 202
icon of scanned page 203
page 203
icon of scanned page 204
page 204
icon of scanned page 205
page 205
Version history
  • Version 1 (January 1, 1988): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts